By Greg Hazley
Monique Greer, a corporate biotech and agency exec, has moved to lead communications for Cell Therapeutics, the publicly traded Seattle-based cancer therapy developer which raised more than $55M in October.
Executive VP/comms. Dan Eramian was terminated, effective Nov. 15, according to a filing. Eramian earned $540K last year and another $675K in stock awards.
Green exits recently acquired Allos Therapeutics, where she was VP of corporate comms. and IR, for a senior VP, corporate comms. and IR, slot at CT.
CEO James Bianco, to whom Greer reports, said the company is transitioning from a “development organization to a commercial organization.”
The company posted a Q3 loss of $20.2M, down from $29.7M for Q3 of 2011.
Greer was a senior associate in WCG’s corporate and IR unit and held earlier corporate comms. posts at Dendreon Corp. and Heska Corp.
CT went public in 1997 and raised $55M in a share offering last month. Its shares are trading at the lower end of its 52-week range of $1.77-$8.25. |